PharmaShots | Incisive News in 3 Shots

Subscribe Now

Neuroendocrine Tumors

Chi-Med's Surufatinib Receives the US FDA's Fast Track Designations for Pancreatic and Non-Pancreatic Neuroendocrine Tumors

Chi-Med's Surufatinib Receives the US FDA's Fast Track Designations for Pancreatic and Non-Pancreatic Neuroendocrine Tumors

April 17, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us